Skip to main content

Year: 2024

Oxford Lane Capital Corp. Schedules Second Fiscal Quarter Earnings Release and Conference Call for November 1, 2024

GREENWICH, Conn., Oct. 25, 2024 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (Nasdaq: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) announced today that it will hold a conference call to discuss its second fiscal quarter earnings on Friday, November 1, 2024 at 9:00 AM ET. The toll-free dial-in number is 1-833-470-1428, access code number 436588. There will be a recorded replay of the call available for 30 days after the call. If you are interested in hearing the recording, please dial 1-866-813-9403. The replay pass-code number is 813197. About Oxford Lane Capital Corp. Oxford Lane Capital Corp. is a publicly-traded registered closed-end management investment company principally investing in debt and equity tranches of collateralized loan obligation (“CLO”) vehicles....

Continue reading

Financial Calendar – Icelandic Salmon

Bíldudalur, 25th of October 2024.  FINANCIAL YEAR 2024 18.11.2024 – Quarterly Report – Q3 18.02.2025 – Quarterly Report – Q4 25.4.2025 – Annual Report 2024 FINANCIAL YEAR 2025 20.05.2025 – Quarterly Report – Q1 18.06.2025 – Annual General Meeting 21.08.2025 – Half-yearly Report 06.11.2025 – Quarterly Report – Q3 Changed date for Q3 2024 reporting Please note that the dates are subject to change. Changes will be communicated through Stock Exchange announcements and the company’s homepage, www.arnarlax.is. The results will be published through the company’s homepage, and other newswires at about 06:30 am CET.  

Continue reading

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference

CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 30, 2024, at 9:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City. Investors interested in arranging a meeting with the Company’s management during the conference should contact the ThinkEquity conference coordinator. A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com. Tonix Pharmaceuticals Holding Corp.* Tonix is a...

Continue reading

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT. An audio webcast of the conference presentation will also be available to investors and the general public and can be accessed in the Investors Section of Alvotech’s website under News and Events – Events and Presentations. After the event, a recording will also be available for 90 days. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused...

Continue reading

Hurco Poised to Pioneer the Future of Manufacturing

INDIANAPOLIS, Oct. 25, 2024 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC), announced today its vision to drive the future of Autonomous Machining Centers by harnessing the power of AI, mechatronics, motion, and simulation technologies. Greg Volovic, President and CEO of Hurco, said, “Building on the successful consolidation of Hurco, Milltronics, and Takumi PC hardware, we plan to transform manufacturing by reshaping industry standards and revolutionizing our market presence with cutting-edge technologies that advance automation and connectivity to address the labor challenges that continue to inhibit growth for our customers.” “Our research and development of AI-driven capabilities, such as feature detection, operation sequencing, and process control, will be critical to realizing our bold vision where Autonomous Machining...

Continue reading

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol “GRCE” effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20th PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it is changing its name to Grace Therapeutics, Inc. (Grace Therapeutics). Grace Therapeutics was the name of the company developing GTx-104 prior to its merger with Acasti in 2021. Grace Therapeutics will begin...

Continue reading

Aspira Women’s Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024

Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipeline AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, has issued a letter to Company shareholders and announced it will host a virtual Research & Development Day on Tuesday, October 29, 2024, at 3:00 pm ET. The R&D Day will highlight the company’s plans for its miRNA development pipeline, including the recently announced award from the Advanced Research Project Agency for Health (ARPA-H)’s Sprint for Women’s Health initiative for ENDOinform™. Details for the event are as follows:Date: October 29, 2024Time: 3:00...

Continue reading

Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) — Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. Management will host a conference call at 8:00 a.m. Eastern Time on November 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13749764. Participants should ask for the Apyx Medical Corporation Call. A live webcast of the call will be accessible via the following link: Apyx...

Continue reading

Fenix Outdoor International Q3 report

FENIX OUTDOOR INTERNATIONAL AGInterim condensed consolidated financial statements for the period ended 30 September 2024 Third quarter 2024-07-01 – 2024-09-30The total income of the Group was TEUR 199,358 (TEUR: 225,846), a decrease of 11.7%. The EBITDA of the Group was TEUR 43,616 (TEUR: 51,416). The operating profit of the Group was TEUR 28,566 (TEUR: 37,391). The profit before tax of the Group was TEUR 23,676 (TEUR: 35,828). The profit after tax of the Group was TEUR 18,485 (TEUR: 27,761). Earnings per share amounted to EUR 1.38 (EUR: 2.08).   Period 2024-01-01 – 2024-09-30The total income of the Group was TEUR 520,999 (TEUR: 565,862), a decrease of 7.9% The EBITDA of the Group was TEUR 78,056 (TEUR: 96,137). The operating profit of the Group was TEUR 34,831 (TEUR: 54,565). The profit before tax of the Group was TEUR 27,689 (TEUR:...

Continue reading

Golden Matrix Group Subsidiary Meridianbet Launches Revolutionary AI-Powered Bet Recommender

Golden Matrix Group Inc,The AI Bet Recommender is designed to offer real-time, personalized betting suggestions, tailored to individual player preferences and habits.LAS VEGAS, Oct. 25, 2024 (GLOBE NEWSWIRE) — Golden Matrix Group Inc. (NASDAQ: GMGI), a leading developer and licensor of online gaming platforms, systems, and content, today announced the launch of the AI-powered Bet Recommender by its sports betting division Meridianbet. The AI Bet Recommender is designed to offer real-time, personalized betting suggestions, tailored to individual player preferences and habits. By processing thousands of data points from sports events and odds parameters, the AI platform ensures that each bet is informed, timely, and highly relevant to the user. Key features include:Data-Driven Decisions: Utilizing vast sports data and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.